Kevin Hershberger Joins Lumicell as Chief Financial Officer
September 18 2018 - 9:18AM
Business Wire
Hershberger brings over 25 years of global
financial management experience from a variety of life science
products and manufacturing companies
Lumicell, Inc., an innovation leader in molecular imaging,
within healthcare focused in cancer, perfusion, wound care and
infection, today announced the addition of Kevin Hershberger
as Chief Financial Officer (CFO).
To Lumicell, Hershberger brings over 25 years of global
financial management experience in a variety of life science
products and manufacturing companies with an extensive range of
expertise and leadership responsibilities. In this highly-visible
leadership role, Hershberger will be responsible for laying the
foundation for the financial success of Lumicell and preparing the
overall business for commercialization.
“In addition to his broad financial acumen and decades-long
career in manufacturing and life sciences companies, Kevin has an
excellent reputation for building strong teams and structuring
successful companies,” said Kelly Londy, CEO, Lumicell. “At
Lumicell, we know that great companies start with great technology
– but great technology doesn’t come to fruition without great
people implementing a strong strategy. Kevin will join our
leadership team and help pave the way for the future success of our
organization.”
“It’s an exciting time to be joining the team at Lumicell,” said
Hershberger. “The company is on the precipice of significant
innovations and making far-reaching strides in bringing its drug
and device therapy to the market where it can help physicians and
patients. But what I’m most excited about is Lumicell’s mission.
Cancer, infection, wound care—battling these tough diseases is
personal. And I look forward to supporting this mission, helping
raise the profile of Lumicell’s technology, and improving people’s
lives.”
Hershberger most recently served as CFO of ReWalk Robotics
(RWLK) where he built out the company’s finance function and helped
bring together a partnership with Harvard University’s Wyss
Institute encompassing a broad licensing and collaboration
agreement to develop a Softsuit Exoskeleton. Prior to ReWalk, he
held leadership roles with NxStage Medical as the Vice President of
Finance, Controller, and Chief Accounting Officer during a period
of significant growth and expansion. Mr. Hershberger also spent
nearly ten years in positions of increasing responsibilities at
Boston Scientific.
About Lumicell, Inc.Lumicell is a technology leader in
the field of image-guided cancer surgery. The company is developing
a novel system that enables real-time detection of tumor tissue in
patients so that no cancer cells are left behind during surgery.
The company’s LUM System has unprecedented ability to see and
remove cancer cells remaining in the surgical cavity – beyond the
margin of the specimen – and has the potential to significantly
improve surgical outcomes and reduce healthcare costs by
eliminating the need for repeat surgeries. Lumicell is
investigating the LUM System in patients undergoing surgery for
breast cancer, prostate cancer, colorectal, esophageal and
pancreatic cancers. Additional future indications are planned to
include surgeries for lung, ovarian, and brain cancers. For more
information, please visit www.lumicell.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180918005541/en/
For LumicellAli Buckneberg,
612-334-5960ali.buckneberg@wordsatwork.com